Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2

Conclusions:
On the basis of the largest series analysed to date, our results show that BRCA1/2 MBCs display distinct pathologic characteristics compared with BRCA1/2 FBCs, and we identified a specific BRCA2-associated MBC phenotype characterised by a variable suggesting greater biological aggressiveness (i.e., high histologic grade). These findings could lead to the development of gender-specific risk prediction models and guide clinical strategies appropriate for MBC management.

Source: Breast Cancer Research - February 9, 2016 Category: Cancer & Oncology Authors: Valentina SilvestriDaniel BarrowdaleAnna MulliganSusan NeuhausenStephen FoxBeth KarlanGillian MitchellPaul JamesDarcy ThullKristin ZornNatalie CarterKatherine NathansonSusan DomchekTimothy RebbeckSusan RamusRobert NussbaumOlufunmilayo OlopadeJohanna Ranta Source Type: research